Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
226.60
-4.98 (-2.15%)
Streaming Delayed Price
Updated: 2:23 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
37
38
Next >
Biogen (BIIB) Q4 2022 Earnings Call Transcript
February 15, 2023
BIIB earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up
February 15, 2023
Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05.
Via
Talk Markets
Why Biogen Stock Is Falling Today
February 15, 2023
Via
Benzinga
Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales
February 15, 2023
The company expects "modest" Leqembi sales, but there's a caveat.
Via
Investor's Business Daily
Cisco, Analog Devices And 3 Stocks To Watch Heading Into Wednesday
February 15, 2023
With US futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
US Stocks Settle Mixed; Investor Optimism Improves
February 15, 2023
The CNN Money Fear and Greed index showed an improvement in the overall sentiment among US investors.
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
February 08, 2023
These stocks soared in the double digits last year.
Via
The Motley Fool
Is Biogen Stock a Buy Now?
January 26, 2023
Its new drug might succeed where the company faltered in 2021.
Via
The Motley Fool
Where Biogen Stands With Analysts
January 24, 2023
Via
Benzinga
FDA Rejects Eli Lilly's Donanemab For Alzheimer's Disease, Needs More Data
January 20, 2023
Via
Benzinga
Investors Are Awaiting The Name Of The New BoJ Governor
February 13, 2023
This week, the Japanese government will officially elect a new Governor of the Bank of Japan to replace Haruhiko Kuroda, whose decade at the Central Bank will end in April.
Via
Talk Markets
Q4 Reporting Season Pushes Past Halfway Mark: Coca-Cola, Cisco Systems, Palantir, Roku Lead Earnings This Week
February 12, 2023
The stock market pulled back in the week ended Feb. 10, dragged by some disappointing earnings and revised December inflation data.
Via
Benzinga
Why Anavex Life Sciences Stock Bolted Higher in January
February 08, 2023
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.
Via
The Motley Fool
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
February 06, 2023
Via
Benzinga
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
January 19, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
February 01, 2023
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.
Via
InvestorPlace
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
January 25, 2023
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.
Via
The Motley Fool
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
January 20, 2023
The company will need to complete its confirmatory study before asking for approval.
Via
Investor's Business Daily
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
January 20, 2023
U.S. stocks look set for a positive start on Friday, reversing course from the sell-off seen in the past three sessions. What Happened: Traders may have to contend with Fed speeches and housing market...
Via
Benzinga
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
January 19, 2023
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.
Via
The Motley Fool
If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today
January 19, 2023
The stock hasn't been a great investment in recent years, but there's hope for a brighter future.
Via
The Motley Fool
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen
January 18, 2023
Via
Benzinga
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
January 17, 2023
The fountain of youth might not be a myth in the future.
Via
The Motley Fool
Elliott Wave Technical Analysis: Biogen Inc.
January 13, 2023
We are looking for further downside into wave C which could take us back to the area of wave 4.
Via
Talk Markets
1 Hot Growth Stock to Buy Now, and 1 to Avoid
January 11, 2023
One company is gearing up for further growth while the other stumbles over itself.
Via
The Motley Fool
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
January 11, 2023
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.
Via
Talk Markets
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
January 10, 2023
There's more to the story with Biogen after receiving good news for Leqembi.
Via
The Motley Fool
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.